Fulcrum Therapeutics 2025 annual meeting passes director elections, say-on-pay, auditor ratification

Fulcrum Therapeutics, Inc.

Class III directors Katina Dorton, Robert Gould, and Kate Haviland elected with 44.6M, 43.8M, and 33.2M votes for, respectively.
Non-binding say-on-pay resolution approved with 46.1M votes for (99.8% of votes cast excluding broker non-votes).
Stockholders selected one year as frequency of future say-on-pay votes (44.9M votes for one year).
Ernst & Young LLP ratified as independent auditor for FY2025 with 49.5M votes for.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.